Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Financing Activities (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Cash from Financing Activities data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 21.01% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $143.4 million, down 7.29%, while the annual FY2025 figure was $143.4 million, 7.29% down from the prior year.
  • Cash from Financing Activities reached $2.3 million in Q4 2025 per TARS's latest filing, down from $2.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $136.6 million in Q1 2025 and bottomed at -$136000.0 in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $26.1 million, with a median of $2.4 million recorded in 2025.
  • The widest YoY moves for Cash from Financing Activities: up 7473300.0% in 2022, down 281.33% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$74000.0 in 2021, then surged by 456.76% to $264000.0 in 2022, then soared by 7384.85% to $19.8 million in 2023, then plummeted by 85.19% to $2.9 million in 2024, then dropped by 21.01% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $2.3 million in Q4 2025, $2.6 million in Q3 2025, and $2.0 million in Q2 2025.